OncoMatch/Clinical Trials/NCT06506838
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Is NCT06506838 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Anlotinib for soft tissue sarcoma.
Treatment: Anlotinib — Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Disease stage
Grade: g2g3
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Exception: eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment
Receipt of any form of anti-tumor treatment within 4 weeks prior to enrollment, including radiotherapy, chemotherapy, molecular targeted therapy (such as angiogenesis inhibitors like sunitinib, sorafenib, imatinib, famitinib, regorafenib), and immunotherapy (eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment)
Cannot have received: chemotherapy
Exception: eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment
Receipt of any form of anti-tumor treatment within 4 weeks prior to enrollment, including radiotherapy, chemotherapy, molecular targeted therapy (such as angiogenesis inhibitors like sunitinib, sorafenib, imatinib, famitinib, regorafenib), and immunotherapy (eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment)
Cannot have received: angiogenesis inhibitor (sunitinib, sorafenib, imatinib, famitinib, regorafenib)
Exception: eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment
Receipt of any form of anti-tumor treatment within 4 weeks prior to enrollment, including radiotherapy, chemotherapy, molecular targeted therapy (such as angiogenesis inhibitors like sunitinib, sorafenib, imatinib, famitinib, regorafenib), and immunotherapy (eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment)
Cannot have received: immunotherapy
Exception: eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment
Receipt of any form of anti-tumor treatment within 4 weeks prior to enrollment, including radiotherapy, chemotherapy, molecular targeted therapy (such as angiogenesis inhibitors like sunitinib, sorafenib, imatinib, famitinib, regorafenib), and immunotherapy (eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment)
Lab requirements
Blood counts
absolute neutrophil count ≥1500/μl, platelet count ≥100,000/μl
Kidney function
creatinine clearance or radioisotope gfr ≥70 ml/min/1.73 m² or serum creatinine within normal limits according to age/gender
Liver function
total bilirubin ≤1.5 × uln, ast or alt <2.5 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify